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Background: Scedosporiosis is associated with a mortality rate of up to 90% in patients suffering from dissemi-
nated infections. Recommended first-line treatment is voriconazole, but epidemiological cut-off values and clin-
ical breakpoints have not been determined.
Objectives: To correlate voriconazole treatment response in mice suffering from disseminated scedosporiosis
with MIC values determined using CLSI broth microdilution, Etest (bioMe´rieux) and disc diffusion.
Methods: Voriconazole MICs for 31 Scedosporium apiospermum strains were determined using CLSI broth micro-
dilution, Etest and disc diffusion. Groups of mice were challenged intravenously with 1 out of 16 S. apiospermum
strains (voriconazole CLSI broth microdilution MIC range: 0.125–8.0 mg/L) and treated with 40 mg/kg voricon-
azole orally by gavage once daily. Efficacy of voriconazole was evaluated by a statistically significant (P,0.05)
reduction in fungal burden in brain.
Results: A categorical agreement of 90.4% was reached for CLSI broth microdilution and disc diffusion and of
93.6% for CLSI broth microdilution and Etest. Correlation of CLSI MICs and in vivo outcome was good, as mice
challenged with strains with an MIC2 mg/L responded to voriconazole therapy in 92.3% and those challenged
with strains with an MIC4 mg/L responded to voriconazole therapy in 33.3%.
Conclusions: CLSI broth microdilution and Etest deliver comparable results that enable a prediction of in vivo out-
come. Our results suggest that voriconazole is able to reduce fungal burden in the brain of 92.3% of all mice chal-
lenged with strains with voriconazole CLSI MICs 2 mg/L, while mice challenged with strains with CLSI MICs
4 mg/L showed limited response to voriconazole treatment.
Introduction
Scedosporiosis and fusariosis are the most frequent mould
infections, after aspergillosis.1 In temperate climate zones,
scedosporiosis is commonly caused by members of the
‘Scedosporium apiospermum species complex’ (containing the for-
mer species: Pseudallescheria ellipsoidea, Pseudallescheria fusoidea,
Pseudallescheria angusta and Pseudallescheria boydii).2 These fungi
cause a broad spectrum of diseases in both immunocompetent
and immunocompromised patients.3 Their special features are a
pronounced neurotropism and resistance to most systemic anti-
fungals (amphotericin B, itraconazole, flucytosine and echinocan-
dins). In immunocompetent patients scedosporiosis is
predominantly localized, but the majority of immunosuppressed
patients (.50%) suffer from disseminated infections (mortality
rates: 58%–75%). Particularly high mortality rates (.90%) are seen
in patients with CNS involvement; in immunosuppressed patients,
Scedosporium disseminates via haematogenous spread, while CNS
scedosporiosis is seen in immunocompetent patients, exclusively
after near-drowning.3,4
Although neither species-specific epidemiological cut-off val-
ues (ECVs) nor clinical breakpoints (CBPs) have been established for
Scedosporium spp., case reports3 and currently available treat-
ment guidelines5 suggest voriconazole (with or without surgery)
as first-line treatment for scedosporiosis. Voriconazole reaches
high CNS-substance levels.4 However, a comprehensive evaluation
of voriconazole treatment outcome in experimental disseminated
scedosporiosis and a correlation with MIC values is lacking.
Therefore, the objectives of this study were to determine if in vivo
efficacy of voriconazole correlates with MIC values and to suggest
a species-specific experimental tentative cut-off value.
VC The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
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In addition, we aimed to evaluate the performance of two
commercial antifungal susceptibility tests [Etest and disc diffu-
sion test (DDT)] in comparison with the gold standard method
(CLSI broth microdilution), to offer alternatives for routine labo-
ratory testing.
Materials and methods
In vitro antifungal susceptibility testing
Twenty-eight clinical isolates and three of environmental origin were used
in the in vitro studies (Table 1). All isolates were previously identified by
sequencing the internal transcribed spacer (ITS) region and the b-tubulin
gene. The sequences were compared using blast against two in-house
databases and the ISHAM ITS database (http://its.mycologylab.org/). The
isolates were subcultured on potato dextrose agar (PDA) for 10 days at
30 C and inocula were prepared as previously described.6
Voriconazole MIC values were determined using: (i) broth microdilution
according to the CLSI M38-A2 document (international gold standard);7 (ii)
disc diffusion using non-supplemented Mueller–Hinton agar and 6 mm
diameter paper discs containing 1.0lg of voriconazole;8 and (iii) Etest
(bioMe´rieux SA, Spain), according to the manufacturer’s instructions. The
strains Paecilomyces variotii ATCC MYA-3630 and Aspergillus fumigatus
ATCC MYA-3626 were used as quality controls.
All in vitro tests were incubated at 35C for 72 h. Broth microdilution
MICs were determined according to CLSI using an endpoint of complete
growth inhibition.7 For disc diffusion, inhibition zone diameters (IZDs)
were measured to the nearest whole millimetre at the point at which
there was a prominent reduction in growth (80%). Slight trailing around
the edges was ignored. Etest MIC corresponded to the gradient concen-
tration where the inhibition ellipse intersected the plastic strip. Etest
MICs were rounded up to the next higher CLSI concentration for com-
parison. Strains were categorized as susceptible if the MIC was 2 mg/L
and resistant if the MIC was 4 mg/L, on the basis of their response to
voriconazole considering as endpoint a reduction in fungal burden in
brain (see the next section). DDTs were read as follows: susceptible (IZD
17 mm), intermediate (IZD 14–16 mm) and resistant (IZD 13 mm).9
The results of Etest and the CLSI broth microdilution method were ana-
lysed for their reproducibility by providing essential agreement values
within +1 and +2 CLSI dilution steps, as previously described.10 The
minimal fungicidal concentration (MFC) was also determined by subcul-
turing 20 lL from each well that showed complete growth inhibition on
PDA plates. The MFC was the lowest drug concentration at which ap-
proximately 99.9% of the original inoculum was killed. Each isolate and
method was tested in triplicate.
Murine model and ethics
Sixteen strains with different susceptibilities to voriconazole (based on CLSI
MIC values) were selected for murine studies (Table 1). Groups of 16 OF-1
male mice (8 for fungal burden and 8 for survival analysis) (Charles River,
Criffa SA, Barcelona, Spain) were immunosuppressed 2 days before the in-
fection and every 5 days with 200 mg/kg cyclophosphamide. On the day of
the infection, OF-1 mice were challenged intravenously with 5%103–
1%104 conidia (inoculum size was adjusted to the virulence of each strain
as tested in a previous study evaluating survival as endpoint; see Table 2)
and treated with voriconazole at 40 mg/kg/day orally with grapefruit juice
by gavage for 7 days.11 The dose was selected on the basis of other studies
evaluating the efficacy of 40 mg/kg voriconazole in OF-1 mice, where
trough serum drug levels obtained were around 4.7–8.2 mg/L after
7–13 days of treatment.12,13 Animals received grapefruit juice during and
2 days before initiation of treatment.12 Brain fungal burden was the study
endpoint, but survival and kidney fungal burden were also analysed. For
comparability, all animals (control and treated groups) were euthanized
after the first animal died in the control group (Table 2). Organs were
worked up as previously described11 for cfu determination/g of tissue. All
animals were housed under standard conditions and care procedures were
supervised and approved under the procedure number 8249, by the
Universitat Rovira i Virgili Animal Welfare and Ethics Committee.
Statistical analysis
The fungal burdens of the control and treated groups were compared using
the Mann–Whitney U-test. The mean survival time (MST) was estimated by
the Kaplan–Meier method and compared among groups using the log rank
test. All statistical analyses were performed with GraphPad Prism 6.0 for
Windows. P values,0.05 were considered statistically significant.
Results
MICs were 0.125–8.0 mg/L for CLSI broth microdilution and 0.094
to .32.0 mg/L for Etest; IZDs ranged from 0 to 40.0 mm. The sus-
ceptibility results for each strain are presented in Table 1. Based on
CLSI broth microdilution, 90.3% of the S. apiospermum strains
were susceptible, 6.5% were intermediate and 3.2% were resist-
ant; with Etest, 96.8% were susceptible and 3.2% were resistant.
Using DDT, 87.1% of strains were susceptible and 12.9% were re-
sistant. The essential levels of agreement between Etest and CLSI
broth microdilution results (Etest MICs within+1 and+2 log2 dilu-
tions of CLSI broth microdilution MICs) were 87.1% and 93.5%, re-
spectively. We found 6.4% of minor errors between Etest and CLSI
broth microdilution and 0% of major and very major errors, with a
93.6% categorical agreement between both methods, while
agreement between CLSI broth microdilution and DDT was 90.4%.
MFCs for all strains exceeded 16.0 mg/L, confirming the fungistatic
activity of voriconazole against S. apiospermum.
Voriconazole resulted in a statistically significant reduction in
fungal burden in brain, compared with the control, in 13 of the 16
strains tested, which coincided, with only one exception, with those
showing MICs 2 mg/L by CLSI broth microdilution testing
(Table 2). Mice challenged with strains of S. apiospermumwith MICs
.2 mg/L failed to respond to therapy in two (FMR 8869,
MIC"4 mg/L and HMM 12-09, MIC"8 mg/L, respectively) out of
three cases. Mice challenged with UANL-OC149 (MIC"4 mg/L)
showed a statistically significant reduction in brain burden when
receiving voriconazole treatment. By using DDT, voriconazole
showed efficacy against all the strains showing an IZD 18 mm
with only one exception (HMM 10-35, IZD"20 mm) and also
against two strains considered resistant in vitro (UANL-OC149 and
HMM 11-47, IZDs"0 mm). With respect to the Etest, voriconazole
showed efficacy against the strains with MICs between 0.094 and
1.5 mg/L with two exceptions (strains HMM 10-35, MIC"0.38 mg/L
and FMR 8869, MIC"0.5 mg/L) and did not against HMM 12-09
(MIC .32 mg/L). Voriconazole treatment significantly reduced the
fungal burden in the brain when mice were challenged with strains
with CLSI MICs 2 mg/L compared with mice challenged with
strains with CLSI MICs 4 mg/L (P"0.039). Based on survival and
fungal burden in kidney, a statistically significant difference
between mice infected with strains with CLSI MICs 2 mg/L and
mice infected with strains with CLSI MICs 4 mg/L was not found
(Table 2).
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Discussion
Mortality rates among patients suffering from disseminated sce-
dosporiosis remain high depending on the underlying disease
(highest in HSCT recipients) and the site of infection (CNS) and can
be up to 90%.3,14 ECVs and CBPs have not been established for the
interpretation of voriconazole MICs, the currently suggested drug
of first-line treatment. Due to the rareness of the disease, these
will remain difficult to establish. In contrast to Scedosporium, ECVs
for amphotericin B and some azoles have been established for
most clinically relevant moulds such as Aspergillus spp., Fusarium
spp. and some Mucorales.15,16
The present study has some limitations that mean that careful
interpretation of the results is required. MIC values of voriconazole
for S. apiospermum .1 mg/L are rare, as MIC90 is ,2 mg/L.
17
Therefore, only a limited set of voriconazole-resistant strains was
tested. There is an absence of pharmacokinetic data to confirm
that voriconazole exposure in the present model is clinically rele-
vant, and the use of grapefruit may increase the efficacy due to
the inhibition of voriconazole metabolism by the mucosal cyto-
chrome enzymes, as previously shown by Liu and Sugar.12
Our results and the results of other murine models of scedo-
sporiosis demonstrated the efficacy of voriconazole against
S. apiospermum, Scedosporium boydii and Scedosporium auran-
tiacum strains with voriconazole MICs between 0.25 and
1 mg/L.11,18,19 Similar to our results, in a guinea pig model, azole
did not show efficacy against one S. apiospermum strain with an
MIC of 8.0 mg/L.20
In the clinical setting, the relevance of susceptibility determin-
ation is largely unknown. Most S. apiospermum isolates have vori-
conazole MICs ,2 mg/L. Considering our results, a therapeutic
failure for patients infected with S. apiospermum strains with MIC
.2 mg/L is likely when there is CNS involvement. However, alterna-
tive therapeutics are lacking due to the multiresistance of these
fungi. Posaconazole is one alternative that demonstrated efficacy
in treating brain abscesses due to S. apiospermum.21 Surgical de-
bridement should be considered whenever possible.5
Overall, our results suggest that voriconazole was able to
reduce fungal burden in the brain of 92.3% of all mice chal-
lenged with S. apiospermum strains with voriconazole CLSI
broth microdilution MICs 2 mg/L and in 33.3% of mice chal-
lenged with strains with MICs4 mg/L. When MICs were deter-
mined by Etest, voriconazole showed efficacy against 86.7% of
strains with an MIC 2 mg/L, while the single strain with a
higher MIC failed to respond. Finally, 91.7% of the strains with
an IZD .17 mm and 50% of strains with an IZD ,13 mm re-
sponded to the voriconazole therapy when fungal burden in
brain was used as the endpoint criterion. In addition, statistical
differences (P"0.039) in brain fungal burden were observed
between strains with CLSI MICs 2 mg/L and 4 mg/L, sug-
gesting a reduced treatment response for voriconazole and
strains with MICs 4 mg/L. However, significant differences
were not found when kidney fungal burden and survival were
studied (P"0.189 and P"0.133, respectively). This might be
due to an organ-specific drug level effect, with higher voricon-
azole concentrations being reached in the kidneys. Survival dif-
ferences failed to reach statistical significance between mice
challenged with strains of either category (2 mg/L or 4 mg/
L), but were significant when compared with the control; this
might be due to the high standard deviations observed within
the groups.
In conclusion, our results suggest that voriconazole might show
efficacy against strains with voriconazole CLSI MICs 2 mg/L. In
addition, Etest and CLSI broth microdilution were found to be suit-
able methods to generate reliable voriconazole MICs for
S. apiospermum strains.
Table 1. In vitro antifungal susceptibility results of 31 isolates of
S. apiospermum using three antifungal susceptibility methods
Strain
MIC (mg/L)a
IZD (mm)bCLSI broth microdilution Etest
HMM 12-14 0.125 0.094 40.0
HMM 12-03 0.25 0.094 35.0
FMR 13015 0.25 0.125 30.0
FMR 13011 0.25 0.125 35.0
HMM 12-04 0.25 0.125 35.0
HMM 12-34 0.25 0.094 30.0
HMM 11-33 0.5 0.19 25.0
HMM 12-36 0.5 0.38 20.0
HMM 11-96 0.5 0.25 25.0
HMM 11-92 0.5 0.19 24.0
HMM 11-97 0.5 0.19 22.0
FMR 8856 0.5 0.25 25.0
HMM 11-93 0.5 0.25 20.0
HMM 11-87 0.5 0.25 25.0
HMM 12-33 0.5 0.25 22.0
HMM 11-36 0.5 0.38 25.0
HMM 10-35 1.0 0.38 20.0
HMM 11-86 1.0 0.75 25.0
HMM 10-34 1.0 1.5 30.0
HMM 11-34 1.0 0.25 25.0
HMM 12-06 1.0 0.75 22.0
FMR 9155 1.0 0.5 20.0
HMM 10-38 1.0 1.5 24.0
FMR 6922 2.0 1.0 20.0
HMM 10-31 2.0 1.0 18.0
HMM 11-47 2.0 1.5 0.0
UANL-PL071 2.0 1.0 20.0
FMR 9167 2.0 1.0 22.0
UANL-OC149 4.0 0.75 0.0
FMR 8869 4.0 0.5 0.0
HMM 12-09 8.0 .32.0 0.0
HMM, Division of Hygiene and Medical Microbiology, Medical University of
Innsbruck, Austria; FMR, Facultat de Medicina de Reus, Spain; UANL,
Universidad Autonoma de Nuevo Leon, Mexico.
aThe broth microdilution method was performed according to CLSI docu-
ment M38-A2,7 and Etest (bioMe´rieux) was performed according to the
manufacturer’s instructions. Strains were considered susceptible if MIC
was 2 mg/L, intermediate if MIC was 4 mg/L and resistant if MIC was
.4 mg/L.
bThe disc diffusion method was performed following the recommenda-
tions of CLSI document M51-A.8 Strains were classified as susceptible if
IZD was 17 mm, intermediate if IZD was between 14 and 16 mm, and
resistant if IZD was13 mm.
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